by Elec23 | Sep 27, 2024 | News&events
VisMederi will be attending the World Vaccine Congress Europe 2024, taking place from October 28th to 31st at Fira de Barcelona, Montjuïc. The significance of this event brings together leading minds from the life sciences and public health fields to discuss the most...
by Elec23 | Sep 24, 2024 | News&events
Fondazione VisMederi has signed an agreement with Trialect Inc., USA, for the program entitled “Trialect Global Medical Education Program.” This initiative aims to provide short-term training and education for biomedical scientists and physicians to enhance the...
by Elec23 | Aug 23, 2024 | News&events
A new study suggests that antibodies produced by vaccinia-based vaccines may neutralize the Monkeypox virus, suggesting potential cross-protection against new threats. The findings emphasize VisMederi’s capability to aid in vaccine development and research...
by Elec23 | Aug 7, 2024 | News&events
VisMederi has been successfully qualified by Qualifyze for conducting activities according to GCLP (Good Clinical Laboratory Practices). Both our laboratory facilities have achieved the prestigious SILVER rating! This outstanding result once again reflects our utmost...
by Elec23 | Jun 12, 2024 | News&events
Another important international study in the field of Monkey Pox and Vaccinia Virus: a sero-epidemiological study assessing the neutralizing response following smallpox vaccination.” The study was conducted in collaboration with VisMederi, the University of...
